{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5"],"submitter":["Antonuzzo L"],"pubmed_abstract":["<h4>Background</h4>Avelumab first-line (1L) maintenance is recommended as the standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without disease progression following 1L platinum-based chemotherapy (PBC). We report results from READY, a real-world study of avelumab 1L maintenance in an Italian compassionate use program (CUP).<h4>Patients and methods</h4>In this prospective, noninterventional CUP, avelumab was provided on physician's request to patients with la/mUC without disease progression following four to six cycles of 1L PBC, after approval by the local ethics committees, per Italian compassionate use regulations.<h4>Results</h4>Between January 2021 and March 2022, 414 patients received avelumab 1L maintenance and were assessable for surviv"],"journal":["ESMO real world data and digital oncology"],"pagination":["100068"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12836724"],"repository":["biostudies-literature"],"pubmed_title":["READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma."],"pmcid":["PMC12836724"],"pubmed_authors":["Maruzzo M","Venturini F","Antonuzzo L","Santini D","Iacovelli R","Bracarda S","Calabro F","Fornarini G","Cerbone L","De Giorgi U","Cullura D","Messina C","Colasanto R","Tambaro R","Carrozza F","Di Lorenzo G","Buti S","Necchi A","Fazzi G"],"additional_accession":[]},"is_claimable":false,"name":"READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma.","description":"<h4>Background</h4>Avelumab first-line (1L) maintenance is recommended as the standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without disease progression following 1L platinum-based chemotherapy (PBC). We report results from READY, a real-world study of avelumab 1L maintenance in an Italian compassionate use program (CUP).<h4>Patients and methods</h4>In this prospective, noninterventional CUP, avelumab was provided on physician's request to patients with la/mUC without disease progression following four to six cycles of 1L PBC, after approval by the local ethics committees, per Italian compassionate use regulations.<h4>Results</h4>Between January 2021 and March 2022, 414 patients received avelumab 1L maintenance and were assessable for surviv","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-07-15T06:19:03.88Z","creation":"2026-06-30T03:23:08.37Z"},"accession":"S-EPMC12836724","cross_references":{"pubmed":["41648646"],"doi":["10.1016/j.esmorw.2024.100068"]}}